Cells are enveloped by a lipid membrane that gives them structure and provides a barrier between the cell and its environment ...
Scientists have discovered that increased expression of a novel long non-coding RNA drives glioblastoma cell growth alongside ...
Acceptance of the New Drug Application is based on findings from a phase 2b portion of the open-label REZILIENT1 clinical trial.
Understanding the patterns of acquired resistance to epidermal growth factor receptor (EGFR) TKI treatment has led to more effective combination therapy and continues to drive development of novel ...
FDA NDA acceptance positions zipalertinib for post-systemic-therapy EGFR ex20ins NSCLC, with a February 27, 2027 PDUFA target ...
CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key ...
(MEMPHIS, Tenn. – November 6, 2025) The enzyme RNA polymerase II transcribes genes into messenger RNA. This process is guided by modifications to the enzyme’s “tail” called phosphorylation patterns.
15d
Lung Cancer Research Foundation Grants Team Science Award Focused on Curing EGFR-Mutant Lung Cancers
The Lung Cancer Research Foundation (LCRF) announces the first recipients of its LCRF Team Science Award on Advancing Therapies Toward Curing EGFR Mutated Lung Cancers. The project, "A novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results